This panel is designed as an open exchange between panel experts and audience members. The objective is to learn how various stakeholders can work together to support new products for alopecia areata and engage the patient voice in therapeutic development.

1. New York
November 14-15, 2016

2. Forward Looking Statements
This presentation contains forward-looking statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Words such as “believes,” “anticipates,” “plans,” “expects,” “indicates,” “will,” “intends,”
“potential,” “suggests” and similar expressions are intended to identify forward-looking statements. These
statements are based on RXi Pharmaceuticals Corporation’s (the “Company”) current beliefs and expectations.
Such statements include, but are not limited to, statements about the future development of the Company’s
products (including timing of clinical trials and related matters associated therewith), the expected timing of
certain developmental milestones, the reporting of unblinded data, potential partnership opportunities, risks that
the potential acquisition of MirImmune may not proceed; the actual realization of anticipated benefits of the
purchase of MirImmune; risks related to our ability to control the timing of the purchase of MirImmune; the
Company’s competition and market opportunity and pro forma estimates. The inclusion of forward-looking
statements should not be regarded as a representation by the Company that any of its plans will be achieved.
Actual results may differ from those set forth in this presentation due to risks and uncertainties in the Company’s
business, including those identified under “Risk Factors” in the Company’s most recently filed Quarterly Report on
Form 10-Q and in other filings the Company periodically makes with the U.S. Securities and Exchange
Commission. The Company does not undertake to update any of these forward-looking statements to reflect a
change in its views or events or circumstances that occur after the date of this presentation.
2

3. RXi Company at a Glance
3
Rx Discovery Preclinical Phase 1 Phase 2
RXI-109
Dermal Scarring
Samcyprone™
Warts
RXI-109
Retinal Scarring
RXI-109
Corneal Scarring
Phase 3
sd-rxRNA / CAR T-cell
Ovarian Cancer
sd-rxRNA / TIL
Melanoma
Consumer
Health
Cosmetic
Lead
Identification
Functional
and Safety
Testing
Consumer / User Testing
RXI-185
Target: Collagenase
(MMP1)
RXI-231
Target: Tyrosinase
(TYR)
Immuno-
Oncology
OphthalmologyDermatology
Once Option is Exercised to Acquire MirImmune, Inc.

4.  Underserved indication with limited therapeutic
options
 RXi has an interest in immune-therapy, and
Samcyprone is topical immune therapy
 Potential for use in other skin indications (warts,
cutaneous tumors………)
 Long standing interest and activity in Dermatology

5.  Topical immune therapy
 Train T-cells to recognize the drug (DPCP) using a
higher concentration of the drug.
 Treat the lesions/area of the scalp with a lower
concentration to trigger T-cells to do their work
 Potential for additional learning in relation to more
selective immune therapy, and possibility to
identify more selective molecular protein targets

6.  Why the decision to focus on AA?
 Why is it worth the technical risk?
 Product development: Drug Delivery
 Which clinical end-points?
 Regulatory approval and commercialization

7.  Academic partners
Experts who can provide guidance to optimize the
treatment and provide info on new potential uses
 Industry partners
Provide through development collaboration a
potential global reach for this important
development
• Patient organizations
Provide support through information sharing with
their members in relation to study sites and
protocols, and provide us with feed-back on what
it is they need most in relation to therapy